公开(公告)号：US20230086152A1

公开(公告)日：2023-03-23

申请号：US17998792

申请日：2021-12-14

申请人： NANJING UNIVERSITY OF CHINESE MEDICINE

发明人： Xu SHEN ,  Jiaying WANG ,  Yujie HUANG ,  Jian LU

IPC分类号： A61K31/4465 ,  A61P25/28

摘要： The present disclosure discloses a new use of desloratadine (DLT) and pharmaceutically acceptable salts thereof in preparing a drug for treating a neurodegenerative disease related to motor dysfunction. The present disclosure shows, through a large number of experimental tests, that desloratadine and the pharmaceutically acceptable salts thereof can improve the state of motor dysfunction in an SOD1-G93A model mouse in the behavioral experimental tests of Rotarod experimental test, gait monitoring experimental test and cage experimental test, and that desloratadine and the pharmaceutically acceptable salts thereof can effectively delay the onset time and prolong the survival cycle of the SOD1-G93A model mouse, and therefore, desloratadine and the pharmaceutically acceptable salts thereof can be used to treat neurodegenerative diseases related to motor dysfunction, including amyotrophic lateral sclerosis.